Study of vedolizumab with other drugs for Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had Crohn's disease for at least 3 months, diagnosed by a scope test.
- Your Crohn's is moderate to severe, based on a score from a colonoscopy.
- You have tried at least one other type of Crohn's medicine (like an interleukin blocker or TNF blocker) and it didn't work well enough, stopped working, or caused bad side effects.
- You have not already tried more than 2 types of advanced therapies or more than 1 medicine from the same class.
- You do not have certain other bowel conditions, like a current abscess, fistula with abscess, or severe narrowing of the intestine.
- You have not had certain infections (like tuberculosis, hepatitis B or C) or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This trial tests combining two medicines, vedolizumab and upadacitinib, to see if they work better together than vedolizumab alone for people with moderate to severe Crohn's disease that hasn't responded well to other treatments.
This trial tests whether switching to vedolizumab works better than increasing your adalimumab dose if your Crohn's symptoms or inflammation are coming back despite treatment. It aims to find the best next step for people whose condition is no longer well-controlled.
This Phase 3 study tests whether vedolizumab can better control moderate-to-severe Crohn’s disease in adults whose symptoms haven’t improved enough with other treatments. You’d need to meet specific symptom scores, recent colonoscopy findings, and safety checks (including infections and vaccination status).
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.